title: [Role of Caelyx in second line treatment of ovarian cancer].
abstract: The authors published their own experiences and results of Caelyx treatment based on 40 ovarian cancer patients treated in 9 different institutions. Patients had been treated with platinum based or platinum-taxol combination chemoterapy. Their average age was 57.2 years (35-80). The average time to progression was 3.8 months (1-8). The effects of the therapy were assessed on 36 patients and the results were 3 CR, 8 PR, 7 SD and 18 PD. Summarised the Caelyx therapy caused improvement in 30.55% of the patients and stabilisation in 19.44%. Supportive therapy was needed in 8 cases.
authors.affiliation: Onkológiai Nôgyógyászati Osztály, Országos Onkológiai Intézet, Budapest 1122, Hungary.
authors.forename: Tamás
authors.initials: T
authors.lastname: Pulay
authors.forename: Sándor
authors.initials: S
authors.lastname: Csömör
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Faluhelyi
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Hernádi
authors.forename: Károly
authors.initials: K
authors.lastname: Krommer
authors.forename: Arpád
authors.initials: A
authors.lastname: Mayer
authors.forename: András
authors.initials: A
authors.lastname: Szánthó
authors.forename: István
authors.initials: I
authors.lastname: Szántó
authors.forename: László
authors.initials: L
authors.lastname: Thurzó
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018450:Disease Progression; D004317:Doxorubicin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin